当前位置：   首页 > 需求大厅

 >  生产研发 

 >  工艺技术 

排行世界的第五大的制药公司寻找合作伙伴，要求提供多种大环结构药物与合成技术，寻找有关大环领域的新药发现。希望此公司提供化学详细的3 d模型。具体请链接：https://www.innocentive.com/ar/challenge/9933642 The Seeker, a top-five big pharma company, is looking for collaboration partners with expertise in the area of macrocycle drug discovery. Specifically, three key areas are of interest: Chemistry partners with access to diverse macrocyclic structures & synthetic expertise In-silico chemistry partners with access to high-throughput 3-D models suitable for macrocycles In-vitro ADME experts with access to membrane systems, beyond PAMPA and Caco-2 This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a preliminary proposal (about 2–4 pages including contact information) to be evaluated by the Seeker with a goal of establishing a collaborative partnership. Upon completion of the evaluation, the Seeker may contact selected Solvers directly to work out terms for a collaboration contract. The monetary value of the contract will vary depending on the amount of work to be delivered and the time frame agreed upon.   [更多]

这是高速度的药物API的片剂压制的一个主要问题。活性药物成分在压冲过程中的冲头被粘住而使片剂重量和剂量有所损失产生不同。我们寻找一种计算片剂压片机高速冲头上剂量和重量损失的模型，用以改进片剂工艺。具体请看下面英文描述：https://www.innocentive.com/ar/challenge/9933670 AWARD: $10,000 USD | DEADLINE: 2/22/15 | ACTIVE SOLVERS: 9 | POSTED: 1/23/15 Solid dosage forms (e.g. tablets) are the preferred dosage unit for pharmaceutical products. These units are produced by compressing particulate formulations. A major problem in the high speed pressing of tablet formulations of pharmaceutical API’s (Active Pharmaceutical Ingredient) is they sometimes tend to stick to the punches during the compression process. This causes weight loss defects in the tablets and thus costly manufacturing defects during production. A model is required to predict sticking of formulations in high speed presses to prevent losses in production. This is an Ideation Challenge with a guaranteed award for at least one submitted solution. Source: InnoCentive Challenge ID: 9933670 Challenge Overview Tablets are the main dosage form of choice for medicines. They have manufactured by compressing formulations which may consist of blended powders or granules. A major problem in the high speed pressing of tablet formulations of new medicines is they sometimes tend to stick to the surfaces of compaction equipment. This causes tablet weight and hence dose reduction and thus costly manufacturing defects during production. The phenomenon is frequently only observed on scale up due to the lengthy run times at large scale and is difficult to reproduce at smaller scales. New models (or partial model concepts) are required to improve the overall modeling of “stickiness” in tablet compression and predict the extent beforehand. Suggestions for improvements to either process route or equipment or to formulation ingredients to prevent sticking from the models are also desired. This is an Ideation Challenge, which has the following unique features: There is a guaranteed award. The awards will be   [更多]

寻找一种载体某些细胞或分子如蛋白质，DNA，RNA，和microRNA，用这些载体来制备高选择性的靶向药物，给药的方法是让药物化合物给药和输送到身体的病灶而达到治疗效果。具体的要求请看下面链接：https://www.innocentive.com/ar/challenge/9933675 AWARD: $30,000 USD | DEADLINE: 2/17/15 | ACTIVE SOLVERS: 108 | POSTED: 1/16/15 Exosomes are membrane-bound vesicles that are produced by many, if not all cell types. Exosomes are able to selectively target certain cells and deliver molecules such as proteins, DNA, RNA, and microRNA. These vesicles are thought to have great potential for targeted drug delivery. The Seeker desires innovative methods for exosome drug loading without significant disruption of the membrane components and properties of the exosome. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933675 Challenge Overview Drug delivery is the method by which pharmaceutical compounds are administered and transported in the body to achieve therapeutic efficacy. Recently, exosomes have been identified as a novel method to deliver drugs in a targeted manner and their potential is derived from natural components such as specific proteins/lipids contained in the membrane of exosomes. Successful delivery of substantial amounts of therapeutic drugs using exosomes is critically dependent on a highly efficient and broadly applicable methodology for loading exosomes with the therapeutic agent, however at present no such technology is available. The Seeker is looking for one or more technologies that will facilitate exosome drug loading without significant disruption of the membrane components and properties of the exosome.   [更多]

资金规模：2000万元 技术要求：工业化成熟可靠的生产技术。有此产品生产 技术者请发产品可行性报告到我司； 中文别名： ;N,N-二甲基-4-氨基苯甲醛;4-(N,N-二甲基)氨基苯甲醛;4-二甲氨基苯甲醛;4-(二甲氨基)苯甲醛;对二甲胺基苯甲醛; 英文名称： 4-Dimethylaminobenzaldehyde 英文别名： ;Ehrlichs;N,N-dimethyl-4-amino benzaldehyde;4-(N,N-Dimethyl)aminobenzaldehyde;p-Dimethylaminobenzaldehyde;4-dimethyl amino benzaldehyde;4-amino-2,3-dimethylbenzaldehyde;P-(Dimethylamino)benzaldehyde; EINECS号： 202-819-0 分子式： C9H11NO 分子量： 149.1897 InChI： InChI=1/C9H11NO/c1-6-7(2)9(10)4-3-8(6)5-11/h3-5H,10H2,1-2H3 密度： 1.097g/cm3 熔点： 70-75℃ 沸点： 305.7°C at 760 mmHg 闪点： 138.7°C 水溶性： 0.3 g/L (20℃)   [更多]

求助丙烯基乙醚的合成工艺,化合物CA登记号(CAS):928-55-2   [更多]

2000元 罗红霉素胶囊75mg 全粉末填充成熟工艺 我公司罗红霉素胶囊75mg 工艺在胶囊填充时装量差异不稳定，工艺复杂，现悬赏求助不经制粒工序，原料加辅料混合直接填充的工艺。工艺走通后给予赏金2000元。   [更多]

苦木的化学成分研究资料------在苦木中分离的化合物，要有具体的分离方法，每个化合物有原始打印的H谱和C谱，有紫外红外更好。有这些资料的联系我，高价格商谈！   [更多]

（1）4-甲氧基-5羟基-铁屎米酮 cas：18110-86-6 （2）4，5-二甲氧基铁屎米酮 cas:18110-87-7 (3) 3-甲基-铁屎米酮-2,6-二酮 有做过苦木生物碱分离的研究生，手里有标准品的我们可以购买，如果能给我们分离也可以，需求量每种40-60mg。价格我们商谈！价钱好说   [更多]

Sibutramine的生产工艺   [更多]

可使生物降解的长效制剂微胶囊技术是一种药物控释技术。在授控的较长的一段时间药物缓慢释放。在过去的二十年中，武田公司已经完善了其专有技术，即具有微胶囊的长效制剂，能在人体的6个多月保持血药浓度。武田希望能有一种技术，即在确定的治疗药物，使用缓释长效制剂微胶囊技术能在任何人体组织上定向使用。具体如下：{https://www.innocentive.com/ar/challenge/9933674} AWARD: varies | DEADLINE: 1/26/15 | ACTIVE SOLVERS: 28 | POSTED: 12/10/14 Depot formulation using a biodegradable microcapsule is one technique for the controlled delivery of pharmaceuticals. The drug is slowly released over an extended period of time in a controlled manner. During the past two decades, Takeda has perfected its proprietary technology, which features a microcapsule depot formulation that maintains drug plasma levels for more than 6 months in humans. Takeda wishes to identify therapeutic agents that will benefit from sustained release through depot formulation using microcapsule technology. This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by the Seeker with a goal of establishing a Takeda funded collaborative partnership. A finder’s fee of $3,000 will be offered at the Seeker’s sole discretion to submission(s) that provide contacts which meet the criteria of the Challenge. Source: InnoCentive Challenge ID: 9933674 Challenge Overview Takeda is well known for its superior depot formulation using microcapsule technology. Controlled sustained release of drugs is achieved using either PLGA (poly-lactic-co-glycolic acid) or PLA (poly-lactic acid) polymer to make microspheres. This core technology is capable of producing injectable formulations that are biodegradable and release drugs over a period of weeks to months. By formulating drugs using this best-in-class approach, Takeda hopes to apply their microcapsule technology to improve the efficacy and safety of known therapeutics compared to the existing administration methods, while providing alternative treatment options to patients with unmet medical needs. In other words, Takeda makes this   [更多]